8-K: Atossa Therapeutics Announces 1-for-15 Reverse Stock Split

Atossa Therapeutics, Inc. will implement a 1-for-15 reverse stock split effective February 2, 2026, to maintain Nasdaq listing compliance.

Summary

• Atossa Therapeutics, Inc. held a Special Meeting of Stockholders on January 20, 2026.
• The Board of Directors approved a 15:1 reverse stock split of common stock, effective 12:01 a.m. Eastern Time on February 2, 2026.
• Common stock is expected to commence trading on a split-adjusted basis at the open of trading on February 2, 2026, under a new CUSIP number (04962H704).
• Each 15 shares of common stock outstanding will be combined into one new share.
• No fractional shares will be issued; stockholders will receive cash equal to the fraction multiplied by the closing price of the common stock on the Nasdaq Stock Market on January 30, 2026.
• The par value per share of common stock will remain unchanged at $0.18.
• Proportionate adjustments will be made to the number of shares subject to outstanding equity awards, their per share exercise price, and the number of shares reserved for future issuance under equity plans.
• Adjustments will also be made to the conversion price of the Series B Convertible Preferred Stock and the number of shares of common stock reserved for issuance pursuant to it.
• Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 5:1 to 20:1, with 33,724,885 votes for, 27,888,393 votes against, and 130,938 abstentions.

Sentiment

Score: 4

Explanation: A reverse stock split is generally viewed as a negative signal, indicating past poor stock performance and a need to maintain exchange listing. While necessary for continued trading, it does not improve underlying fundamentals and often leads to further price erosion due to negative investor sentiment. The approval by shareholders and the proactive step to maintain listing are minor positives, but the overall context is challenging.

Positives

• The reverse stock split aims to increase the per-share price, which is often necessary to meet minimum bid price requirements for continued listing on the Nasdaq Capital Market.
• Maintaining Nasdaq listing ensures continued liquidity and visibility for the company's stock, which can be beneficial for investors.
• Stockholders approved the measure, indicating support for the company's strategy to maintain listing compliance.

Negatives

• A reverse stock split often signals a prolonged period of low stock price performance, which can be a negative indicator for investors.
• The action itself does not change the company's underlying value or operational performance.
• There is a risk that the stock price may continue to decline post-split, potentially negating the intended effect of maintaining a higher share price.
• Fractional shares will be cashed out, potentially forcing some shareholders to sell a portion of their holdings.

Risks

• The reverse stock split may not achieve its intended purpose of maintaining the stock price above Nasdaq's minimum bid requirement over the long term.
• Investor perception of a reverse stock split can be negative, potentially leading to further selling pressure on the stock.
• The company's market capitalization remains unchanged immediately after the split, but the reduced number of shares could lead to lower trading volume.
• The cash payment for fractional shares may result in a taxable event for some stockholders.

Future Outlook

The common stock is expected to commence trading on a split-adjusted basis on February 2, 2026, under a new CUSIP number, and will continue to trade on the Nasdaq Stock Market under the symbol ATOS. This indicates an expectation of continued listing on Nasdaq.

Management Comments

• The Certificate of Amendment to the Certificate of Incorporation was executed by Steven C. Quay, M.D., Ph.D., Chairman of the Board, President and Chief Executive Officer, on January 20, 2026.

Industry Context

Reverse stock splits are common actions taken by companies, particularly in the biotechnology or small-cap sectors, when their stock price falls below exchange minimums (e.g., Nasdaq's $1.00 bid price requirement). This move aims to regain compliance and maintain institutional investor interest, as many funds have mandates against investing in 'penny stocks.' While necessary for listing, it does not inherently improve the company's business fundamentals or prospects.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action for companies facing delisting from major exchanges due to low share prices, similar to actions taken by other small-cap biotech firms when facing similar challenges.
• The 1-for-15 ratio is within the typical range (often 1-for-5 to 1-for-20) seen in such situations, aiming to significantly boost the per-share price.
• The provision for cash in lieu of fractional shares is also a standard practice to simplify shareholding post-split.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a 15:1 ratio, with the per-share price theoretically increasing proportionally. Those holding fewer than 15 shares or resulting in fractional shares will receive cash, potentially forcing a partial liquidation of their investment. The goal is to maintain Nasdaq listing, which benefits all shareholders by preserving liquidity.
• Employees (with equity awards): Equity awards (options, RSUs) will be proportionately adjusted in terms of the number of shares and exercise price, ensuring their value is preserved on a pre-split equivalent basis.
• Preferred Stockholders: The conversion price and number of shares reserved for issuance related to Series B Convertible Preferred Stock will be proportionately adjusted.

Next Steps

• The common stock will commence trading on a split-adjusted basis at the open of trading on February 2, 2026.
• The company will issue cash payments for fractional shares based on the closing price on January 30, 2026.
• The company will continue to trade on the Nasdaq Stock Market under the symbol ATOS.

Key Dates

Recommendation

A reverse stock split is a necessary corporate action to maintain Nasdaq listing, which is crucial for liquidity and institutional investment. While it addresses a technical requirement, it does not fundamentally change the company's business prospects or financial health. Investors should hold to observe if the company can leverage its continued listing to improve operational performance and achieve sustainable growth, rather than selling purely based on the split, which is often a short-term negative sentiment event. A 'hold' allows for assessment of post-split performance and any subsequent strategic developments.

Keywords

Atossa Therapeutics, ATOS, Reverse Stock Split, Nasdaq Listing, Corporate Action, Stockholder Meeting, Equity Adjustment, Biotechnology, Pharmaceuticals